Stéphane Dalle

25.5k total citations · 1 hit paper
325 papers, 9.1k citations indexed

About

Stéphane Dalle is a scholar working on Oncology, Molecular Biology and Dermatology. According to data from OpenAlex, Stéphane Dalle has authored 325 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 174 papers in Oncology, 102 papers in Molecular Biology and 85 papers in Dermatology. Recurrent topics in Stéphane Dalle's work include Cancer Immunotherapy and Biomarkers (81 papers), Cutaneous Melanoma Detection and Management (75 papers) and Cutaneous lymphoproliferative disorders research (70 papers). Stéphane Dalle is often cited by papers focused on Cancer Immunotherapy and Biomarkers (81 papers), Cutaneous Melanoma Detection and Management (75 papers) and Cutaneous lymphoproliferative disorders research (70 papers). Stéphane Dalle collaborates with scholars based in France, United States and Spain. Stéphane Dalle's co-authors include L. Thomas, B. Balme, D. Bataille, Alice Phan, S. Ronger-Savlé, Safia Costes, S. Debarbieux, Jerrold M. Olefsky, Christophe Broca and Gyslaine Bertrand and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Stéphane Dalle

301 papers receiving 9.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

2019 703 citations Georgina V. Long, Reinhard Dummer et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Stéphane Dalle	4.0k	3.0k	2.0k	1.8k	1.6k	325	9.1k
Anna Sapino	4.1k 1.0×	3.3k 1.1×	1.1k 0.5×	763 0.4×	513 0.3×	336	11.0k
Takuya Moriya	2.7k 0.7×	3.1k 1.0×	729 0.4×	395 0.2×	706 0.4×	336	9.3k
Stefania Staibano	2.4k 0.6×	2.8k 0.9×	725 0.4×	646 0.4×	730 0.5×	229	6.5k
Wolter J. Mooi	4.5k 1.1×	5.8k 1.9×	1.2k 0.6×	521 0.3×	1.6k 1.0×	111	12.0k
Yusuke Nakamura	2.1k 0.5×	4.6k 1.5×	1.1k 0.5×	238 0.1×	1.5k 0.9×	160	10.4k
Lawrence Zukerberg	3.9k 1.0×	3.4k 1.1×	780 0.4×	358 0.2×	567 0.4×	155	9.6k
Naoyuki Kamatani	1.0k 0.3×	2.8k 0.9×	1.6k 0.8×	288 0.2×	1.3k 0.9×	179	8.9k
Sanford H. Barsky	4.0k 1.0×	3.6k 1.2×	489 0.2×	793 0.4×	599 0.4×	160	10.1k
Ronald A. DeLellis	2.6k 0.6×	2.6k 0.9×	1.8k 0.9×	247 0.1×	618 0.4×	204	9.8k
Ryohei Katoh	1.1k 0.3×	1.9k 0.6×	781 0.4×	294 0.2×	553 0.4×	211	6.7k

Countries citing papers authored by Stéphane Dalle

Since Specialization

Citations

This map shows the geographic impact of Stéphane Dalle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Dalle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Dalle more than expected).

Fields of papers citing papers by Stéphane Dalle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Dalle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Dalle. The network helps show where Stéphane Dalle may publish in the future.

Co-authorship network of co-authors of Stéphane Dalle

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Dalle. A scholar is included among the top collaborators of Stéphane Dalle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Dalle. Stéphane Dalle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ascierto, Paolo A., Michele Del Vecchio, Barbara Merelli, et al.. (2025). 1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma. Annals of Oncology. 36. S887–S888.

Lipson, Evan J., F. Stephen Hodi, Hussein Tawbi, et al.. (2025). Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. European Journal of Cancer. 225. 115547–115547. 1 indexed citations

Dalle, Stéphane, Laurent Mortier, O. Dereure, et al.. (2024). Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight‐adjusted dose, a multicenter observational study. Cancer. 131(1). e35679–e35679. 2 indexed citations

Freymond, N., Gilles Boschetti, Fanny Lebossé, et al.. (2024). Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary Board. JCO Oncology Practice. 21(3). 342–350. 3 indexed citations

Mortier, Laurent, Stéphane Dalle, O. Dereure, et al.. (2024). When to stop immunotherapy for advanced melanoma: Emulation of target trials.. Journal of Clinical Oncology. 42(16_suppl). 9521–9521.

Dummer, Reinhard, Jean‐Jacques Grob, Caroline Robert, et al.. (2024). Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.. Journal of Clinical Oncology. 42(16_suppl). 9506–9506. 2 indexed citations

Durand, Simon, et al.. (2024). ZEB1 controls a lineage-specific transcriptional program essential for melanoma cell state transitions. Oncogene. 43(20). 1489–1505. 5 indexed citations

Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, et al.. (2024). Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. Journal of Clinical Oncology. 43(13). 1546–1552. 24 indexed citations

Cario, Muriel, Simon Durand, Manfred Schartl, et al.. (2024). Cancer Cell Biomechanical Properties Accompany Tspan8-Dependent Cutaneous Melanoma Invasion. Cancers. 16(4). 694–694. 2 indexed citations

10.

Tawbi, Hussein A., F. Stephen Hodi, Evan J. Lipson, et al.. (2023). Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.. Journal of Clinical Oncology. 41(16_suppl). 9502–9502. 7 indexed citations

11.

Dalle, Stéphane, Thomas U. Marron, Caroline Robert, et al.. (2023). 1051P Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: Interim results from the ATLAS-IT-05 trial. Annals of Oncology. 34. S636–S636. 4 indexed citations

12.

Lebossé, Fanny, Xavier Quantin, C. Lesage, et al.. (2023). Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Reports. 5(6). 100719–100719. 43 indexed citations

13.

Lazar, Ikrame, Emily Clement, David Estève, et al.. (2022). Adipocyte Extracellular Vesicles Decrease p16INK4A in Melanoma: An Additional Link between Obesity and Cancer. Journal of Investigative Dermatology. 142(9). 2488–2498.e8. 6 indexed citations

14.

Tonon, Laurie, Jonathan Lopez, B. Balme, et al.. (2022). ZEB1 transcription factor promotes immune escape in melanoma. Journal for ImmunoTherapy of Cancer. 10(3). e003484–e003484. 55 indexed citations

15.

Cugnet‐Anceau, Christine, Stéphane Dalle, Karim Chikh, et al.. (2021). Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). Cancers. 13(8). 1944–1944. 23 indexed citations

16.

Abeillon, J., Stéphane Dalle, Souad Assaad, et al.. (2020). Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up. Journal of Clinical Medicine. 9(10). 3280–3280. 24 indexed citations

17.

Lazar, Ikrame, Emily Clement, Stéphanie Dauvillier, et al.. (2016). Adipocyte Exosomes Promote Melanoma Aggressiveness through Fatty Acid Oxidation: A Novel Mechanism Linking Obesity and Cancer. Cancer Research. 76(14). 4051–4057. 281 indexed citations

18.

Dalle, Stéphane, Lina Reslan, Frank Herting, et al.. (2011). Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101. Molecular Cancer Therapeutics. 10(1). 178–185. 97 indexed citations

19.

Wong, Winifred P.S., Joseph P. Tiano, Sylvia C. Hewitt, et al.. (2010). Extranuclear estrogen receptor-α stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis. Proceedings of the National Academy of Sciences. 107(29). 13057–13062. 106 indexed citations

20.

Kérob, Delphine, Raphaël Porcher, O Vérola, et al.. (2010). Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients. Clinical Cancer Research. 16(12). 3288–3295. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact